Dronabinol for the treatment of cannabis dependence: A randomized, double-blind, placebo-controlled trial

Drug and Alcohol Dependence

Volumn 116, Issue 1-3, 2011, Pages 142-150

  Levin, Frances R ^a,b   Mariani, John J ^a,b   Brooks, Daniel J ^b   Pavlicova, Martina ^c   Cheng, Wendy ^a,b   Nunes, Edward V ^a,b  

^a NEW YORK STATE PSYCHIATRIC INSTITUTE   (United States)

^b College of Physicians and Surgeons of Columbia University ^*  (United States)

^c Och Spine at New York Presbyterian Hospitals   (United States)

Author keywords

Cannabis dependence; Cannabis withdrawal; Dronabinol; Marijuana dependence; Marinol

Indexed keywords

DRONABINOL; PLACEBO;

ABSTINENCE; ADULT; ARTICLE; CANNABIS ADDICTION; CONTROLLED STUDY; DIZZINESS; DOUBLE BLIND PROCEDURE; DROWSINESS; DRUG DOSE INCREASE; DRUG DOSE REDUCTION; DRUG DOSE TITRATION; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; EVENING DOSAGE; FEMALE; HUMAN; HYPERTENSION; MAJOR CLINICAL STUDY; MALE; MOTIVATIONAL ENHANCEMENT THERAPY; NIGHTMARE; OUTCOME ASSESSMENT; PARALLEL DESIGN; PRIORITY JOURNAL; PSYCHOTHERAPY; RANDOMIZED CONTROLLED TRIAL; SLEEP DISORDER; TREATMENT DURATION; WITHDRAWAL SYNDROME;

ADULT; BEHAVIOR, ADDICTIVE; CANNABINOIDS; DOUBLE-BLIND METHOD; DRUG ADMINISTRATION SCHEDULE; FEMALE; HUMANS; MALE; MARIJUANA ABUSE; MARIJUANA SMOKING; MIDDLE AGED; PLACEBOS; PSYCHOTHERAPY; PSYCHOTROPIC DRUGS; SUBSTANCE WITHDRAWAL SYNDROME; TETRAHYDROCANNABINOL;

CANNABIS; CANNABIS SATIVA;

EID: 79957582201     PISSN: 03768716     EISSN: 18790046     Source Type: Journal    
DOI: 10.1016/j.drugalcdep.2010.12.010     Document Type: Article

References (64)

1. American Psychiatric Association (APA) Diagnostic and Statistical Manual of Mental Disorders 1994, American Psychiatric Association, Washington, DC. 4th edition.
2. Anton R.F., O'Malley S.S., Ciraulo D.A., Cisler R.A., Couper D., Donovan D.M., Gastfriend D.R., Hosking J.D., Johnson B.A., LoCastro J.S., Longabaugh R., Mason B.J., Mattson M.E., Miller W.R., Pettinati H.M., Randall C.L., Swift R., Weiss R.D., Williams L.D., Zweben A. Combined pharmacotherapies and behavioral interventions for alcohol dependence: the COMBINE study: a randomized controlled trial. JAMA 2006, 295:2003-2017.
3. Budney A.J., Radonovich K.J., Higgins S.T., Wong C.J. Adults seeking treatment for marijuana dependence: a comparison with cocaine-dependent treatment seekers. Exp. Clin. Psychopharmacol. 1998, 6:419-426.
4. Budney A.J., Novy P.L., Hughes J.R. Marijuana withdrawal among adults seeking treatment for marijuana dependence. Addiction 1999, 94:1311-1322.
5. Budney A.J., Moore B.A., Rocha H.L., Higgins S.T. Clinical trial of abstinence-based vouchers and cognitive-behavioral therapy for cannabis dependence. J. Consult. Clin. Psychol. 2006, 74:307-316.
6. Budney A.J., Vandrey R.G., Hughes J.R., Moore B.A., Bahrenburg B. Oral delta-9-tetrahydrocannabinol suppresses cannabis withdrawal symptoms. Drug Alcohol Depend. 2007, 86:22-29.
7. Budney A.J., Vandrey R.G., Hughes J.R., Thostenson J.D., Bursac Z. Comparison of cannabis and tobacco withdrawal: severity and contribution to relapse. J. Subst. Abuse Treat. 2008, 35:362-368.
8. Calhoun S.R., Galloway G.P., Smith D.E. Abuse potential of dronabinol (Marinol). J. Psychoactive Drugs 1998, 30:187-196.
9. Carpenter K.M., McDowell D., Brooks D.J., Cheng W.Y., Levin F.R. A preliminary trial: double-blind comparison of nefazodone, bupropion-SR, and placebo in the treatment of cannabis dependence. Am. J. Addict. 2009, 18:53-64.
10. Carroll K.M., Rounsaville B.J., Gordon L.T., Nich C., Jatlow P., Bisighini R.M., Gawin F.H. Psychotherapy and pharmacotherapy for ambulatory cocaine abusers. Arch. Gen. Psychiatry 1994, 51:177-187.
11. Carroll K.M., Kosten T.R., Rounsaville B.J. Choosing a behavioral therapy platform for pharmacotherapy of substance users. Drug Alcohol Depend. 2004, 75:123-134.
12. Comer S.D., Collins E.D., Fischman M.W. Buprenorphine sublingual tablets: effects on IV heroin self-administration by humans. Psychopharmacology (Berl.) 2001, 154:28-37.
13. Compton W.M., Grant B.F., Colliver J.D., Glantz M.D., Stinson F.S. Prevalence of marijuana use disorders in the United States: 1991-1992 and 2001-2002. JAMA 2004, 291:2114-2121.
14. Cooper Z.D., Haney M. Opioid antagonism enhances marijuana's effects in heavy marijuana smokers. Psychopharmacology (Berl.) 2010, 211:141-148.
15. Copeland J., Swift W., Roffman R., Stephens R. A randomized controlled trial of brief cognitive-behavioral interventions for cannabis use disorder. J. Subst. Abuse Treat. 2001, 21:55-64. discussion 5-6.
16. Del Boca F.K., Kranzler H.R., Brown J., Korner P.F. Assessment of medication compliance in alcoholics through UV light detection of a riboflavin tracer. Alcohol Clin. Exp. Res. 1996, 20:1412-1417.
17. Dennis M., Godley S.H., Diamond G., et al. The Cannabis Youth Treatment (CYT) Study: main findings from two randomized trials. J. Subst. Abuse Treat. 2004, 27:197-213.
18. Donny E.C., Brasser S.M., Bigelow G.E., Stitzer M.L., Walsh S.L. Methadone doses of 100mg or greater are more effective than lower doses at suppressing heroin self-administration in opioid-dependent volunteers. Addiction 2005, 100:1496-1509.
19. First M.B., Spitzer R.L., Gibbon M., William J.B.W. Structured Clinical Interview for DSM-IV Axis I Disorders-Patient Edition (SCID-I/P, Patient Verision 2.0) 1995, Biometrics Research Department, New York State Psychiatric Institute.
20. Garrison G.D., Dugan S.E. Varenicline: a first-line treatment option for smoking cessation. Clin. Ther. 2009, 31:463-491.
21. Haney M., Hart C.L., Vosburg S.K., Nasser J., Bennett A., Zubaran C., Foltin R.W. Marijuana withdrawal in humans: effects of oral THC or divalproex. Neuropsychopharmacology 2004, 29:158-170.
22. Haney M., Hart C.L., Vosburg S.K., Comer S.D., Reed S.C., Foltin R.W. Effects of THC and lofexidine in a human laboratory model of marijuana withdrawal and relapse. Psychopharmacology (Berl.) 2008, 197:157-168.
23. Haney M., Ward A.S., Comer S.D., Hart C.L., Foltin R.W., Fischman M.W. Bupropion SR worsens mood during marijuana withdrawal in humans. Psychopharmacology (Berl.) 2001, 155:171-179.
24. Haney M., Hart C.L., Ward A.S., Foltin R.W. Nefazodone decreases anxiety during marijuana withdrawal in humans. Psychopharmacology (Berl.) 2003, 165:157-165.
25. Haney M., Hart C.L., Vosburg S.K., Comer S.D., Reed S.C., Cooper Z.D., Foltin R.W. Effects of baclofen and mirtazapine on a laboratory model of marijuana withdrawal and relapse. Psychopharmacology (Berl.) 2010, 211:233-244.
26. Hart C.L., Haney M., Ward A.S., Fischman M.W., Foltin R.W. Effects of oral THC maintenance on smoked marijuana self-administration. Drug Alcohol Depend. 2002, 67:301-309.
27. Hart C.L., Haney M., Vosburg S.K., Comer S.D., Foltin R.W. Reinforcing effects of oral Delta9-THC in male marijuana smokers in a laboratory choice procedure. Psychopharmacology (Berl.) 2005, 181:237-243.
28. Heishman S.J., Singleton E.G., Liguori A. Marijuana Craving Questionnaire: development and initial validation of a self-report instrument. Addiction 2001, 96:1023-1034.
29. Heishman S.J., Evans R.J., Singleton E.G., Levin K.H., Copersino M.L., Gorelick D.A. Reliability and validity of a short form of the Marijuana Craving Questionnaire. Drug Alcohol Depend. 2009, 102:35-40.
30. Hughes J.R., Peters E.N., Callas P.W., Budney A.J., Livingston A.E. Attempts to stop or reduce marijuana use in non-treatment seekers. Drug Alcohol Depend. 2008, 97:180-184.
31. Johnson B.A., Ait-Daoud N., Roache J.D. The COMBINE SAFTEE: a structured instrument for collecting adverse events adapted for clinical studies in the alcoholism field. J. Stud. Alcohol Suppl. 2005, (15):157-167. discussion 40.
32. Johnson B.A., Ait-Daoud N., Akhtar F.Z., Javors M.A. Use of oral topiramate to promote smoking abstinence among alcohol-dependent smokers: a randomized controlled trial. Arch. Intern. Med. 2005, 165:1600-1605.
33. Kosten T., Oliveto A., Feingold A., Poling J., Sevarino K., McCance-Katz E., Stine S., Gonzalez G., Gonsai K. Desipramine and contingency management for cocaine and opiate dependence in buprenorphine maintained patients. Drug Alcohol Depend. 2003, 70:315-325.
34. Levin F.R., McDowell D., Evans S.M., Nunes E., Akerele E., Donovan S., Vosburg S.K. Pharmacotherapy for marijuana dependence: a double-blind, placebo-controlled pilot study of divalproex sodium. Am. J. Addict. 2004, 13:21-32.
35. Levin F.R., Brooks D.J., Bisaga A., Raby W., Rubin E., Aharonovich E., Nunes E.V. Severity of dependence and motivation for treatment: comparison of marijuana- and cocaine-dependent treatment seekers. J. Addict. Dis. 2006, 25:33-41.
36. Levin F.R., Mariani J.J., Brooks D.J., Xie S., Murray K.A. Delta9-tetrahydrocannabivarin testing may not have the sensitivity to detect marijuana use among individuals ingesting dronabinol. Drug Alcohol Depend. 2010, 106:65-68.
37. Levine J., Schooler N.R. SAFTEE: a technique for the systematic assessment of side effects in clinical trials. Psychopharmacol. Bull. 1986, 22:343-381.
38. Lutfy K., Cowan A. Buprenorphine: a unique drug with complex pharmacology. Curr. Neuropharmacol. 2004, 2:395-402.
39. Mariani J.J., Brooks D., Haney M., Levin F.R. Quantification and comparison of marijuana smoking practices: blunts, joints, and pipes. Drug Alcohol Depend. 2010, September 20 [Epub ahead of print].
40. Martin J., Zweben J.E., Thomas P. Opioid maintenance treatment. Principles of Addiction Medicine 2009, 671-688. Lippincott Williams & Wilkins, Philadelphia. 4th edition. R.K. Reis, D.A. Fiellin, S.C. Miller, R. Saitz (Eds.).
41. Mattick R.P., Breen C., Kimber J., Davoli M. Methadone maintenance therapy versus no opioid replacement therapy for opioid dependence. Cochrane Database Syst. Rev. 2009, (3):CD002209.
42. McRae-Clark A.L., Carter R.E., Killeen T.K., Carpenter M.J., Wahlquist A.E., Simpson S.A., Brady K.T. A placebo-controlled trial of buspirone for the treatment of marijuana dependence. Drug Alcohol Depend. 2009, 105:132-138.
43. MTPRG.Marijuana Treatment Project Research Group Brief treatments for cannabis dependence: findings from a randomized multisite trial. J. Consult. Clin. Psychol. 2004, 72:455-466.
44. Nordstrom B.R., Levin F.R. Treatment of cannabis use disorders: a review of the literature. Am. J. Addict. 2007, 16:331-342.
45. Nunes E.V., McGrath P.J., Quitkin F.M., Ocepek-Welikson K., Stewart J.W., Koenig T., Wager S., Klein D.F. Imipramine treatment of cocaine abuse: possible boundaries of efficacy. Drug Alcohol Depend. 1995, 39:185-195.
46. Nunes E.V., Quitkin F.M., Donovan S.J., Deliyannides D., Ocepek-Welikson K., Koenig T., Brady R., McGrath P.J., Woody G. Imipramine treatment of opiate-dependent patients with depressive disorders. A placebo-controlled trial. Arch. Gen. Psychiatry 1998, 55:153-160.
47. NSDUH. Substance Abuse and Mental Health Services Administration, 2009 Results from the, 2008 National Survey on Drug Use and Health: National Findings (Office of Applied Studies, NSDUH Series H-32, DHHS Publication No. SMA 07-4293). Rockville, MD. Available online at (accessed on September 2009). http://oas.samhsa.gov/nsduh/2k8nsduh/2k8Results.pdf.
48. Poling J., Oliveto A., Petry N., Sofuoglu M., Gonsai K., Gonzalez G., Martell B., Kosten T.R. Six-month trial of bupropion with contingency management for cocaine dependence in a methadone-maintained population. Arch. Gen. Psychiatry 2006, 63:219-228.
49. Reus V.I., Smith B.J. Multimodal techniques for smoking cessation: a review of their efficacy and utilisation and clinical practice guidelines. Int. J. Clin. Pract. 2008, 62:1753-1768.
50. Rollema H., Chambers L.K., Coe J.W., Glowa J., Hurst R.S., Lebel L.A., Lu Y., Mansbach R.S., Mather R.J., Rovetti C.C., Sands S.B., Schaeffer E., Schulz D.W., Tingley F.D., Williams K.E. Pharmacological profile of the alpha4beta2 nicotinic acetylcholine receptor partial agonist varenicline, an effective smoking cessation aid. Neuropharmacology 2007, 52:985-994.
51. SAMHSA, 2009. Substance Abuse and Mental Health Services Administration, Office of Applied Studies. (accessed on September). http://oas.samhsa.gov/nsduh/2k8nsduh/2k8Results.pdf.
52. SAS SAS PROC GENMOD 2000, SAS Institute, Cary, NC.
53. Schmitz J.M., Mooney M.E., Moeller F.G., Stotts A.L., Green C., Grabowski J. Levodopa pharmacotherapy for cocaine dependence: choosing the optimal behavioral therapy platform. Drug Alcohol Depend. 2008, 94:142-150.
54. Schottenfeld R.S., Chawarski M.C., Mazlan M. Maintenance treatment with buprenorphine and naltrexone for heroin dependence in Malaysia: a randomised, double-blind, placebo-controlled trial. Lancet 2008, 371:2192-2200.
55. Shah S.D., Wilken L.A., Winkler S.R., Lin S.J. Systematic review and meta-analysis of combination therapy for smoking cessation. J. Am. Pharm. Assoc. (2003) 2008, 48:659-665.
56. Sobell L.C., Sobell M.B. Timeline Follow-back: A Technique for Assessing Self-Reported Alcohol Consumption in Measuring Alcohol Consumption 1992, Humana Press, Totowa, NJ.
57. Stanger C., Budney A.J., Kamon J.L., Thostensen J. A randomized trial of contingency management for adolescent marijuana abuse and dependence. Drug Alcohol Depend. 2009, 105:240-247.
58. Stead L.F., Perera R., Bullen C., Mant D., Lancaster T. Nicotine replacement therapy for smoking cessation. Cochrane Database Syst. Rev. 2008, (1):CD000146.
59. Steinberg K.L., Roffman R.A., Carroll K.M., McRee B., Babor T.F., Miller M. Brief Counseling for Marijuana Dependence, Vol DHHS Publication No. (SMA) 05-4022 2005, Center for Substance Abuse Treatment, Substance Abuse and Mental Health Services Administration, Rockville, MD.
60. Stephens R.S., Roffman R.A., Curtin L. Comparison of extended versus brief treatments for marijuana use. J. Consult. Clin. Psychol. 2000, 68:898-908.
61. TEDS, 2007. Substance Abuse and Mental Health Services Administration, Office of Applied Studies. Treatment Episode Data Set (TEDS). Highlights. National Admissions to Substance Abuse Treatment Services, DASIS Series: S-45, DHHS Publication No. (SMA) 09-4360, Rockville, MD., 2009. http://www.dasissamhsagov/teds07/tedshigh2k7pdf.
62. Tiffany S.T., Singleton E., Haertzen C.A., Henningfield J.E. The development of a cocaine craving questionnaire. Drug Alcohol Depend. 1993, 34:19-28.
63. Vandrey R., Haney M. Pharmacotherapy for cannabis dependence: how close are we?. CNS Drugs 2009, 23:543-553.
64. Wang D., Connock N., Barton P., Fry-Smith A., Aveyard P., Moore D. Cut down to quit with nicotine replacement therapies in smoking cessation: a systematic review of effectiveness and economic analysis. Health Technol. Assess. 2008, 12:1-135.